Abstract
Calcium/calmodulin-dependent protein kinase IIδ (CaMKIIδ) is an important regulator of cardiac contractile function and dysfunction and may be an unwanted secondary target for anti-cancer drugs such as sunitinib and imatinib that have been reported to alter cardiac performance. This study aimed to determine whether anti-cancer kinase inhibitors may affect CaMKII activity and expression when administered in vivo.
| Original language | English |
|---|---|
| Journal | British Journal of Pharmacology |
| Early online date | 4 Jun 2015 |
| DOIs | |
| Publication status | Published - 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- cardiac contractility
- calcium/calmodulin-dependent protein kinase II
- imatinib
- sunitinib
- cardiotoxicity
- phosphorylation
Fingerprint
Dive into the research topics of 'Effect of acute and chronic sunitinib treatment on cardiac function and CaMKII'. Together they form a unique fingerprint.Profiles
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver